Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA)

Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting

BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster presentation(2) of blinatumomab data at the 14th Congress of European Hematology Association (EHA) taking place from June 4-7, 2009, in Berlin, Germany. Interim data from the phase 2 clinical trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentation, while an update from the phase 1 trial with blinatumomab in patients with non-Hodgkin's lymphoma (NHL) will be presented in a poster and include additional data on the durability of responses last presented at the American Society of Hematology meeting in December 2008 and efficacy data from additional patients.

Micromet also announced a poster presentation(3) for adecatumumab at the 45th annual meeting of ASCO taking place from May 29 - June 2 in Orlando, Florida. The new data will include an update of the data presented at the European Society of Oncology (ESMO) meeting in October of 2008.

(1) Topp et al, (2009) Blinatumomab (anti-CD19 BiTE(R)) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study. 14th Congress of EHA (2009), abstract number 482; oral presentation on June 6 in Hall 15.2 at 8:15 AM.

(2) Klinger, et al. (2009) Pharmacodynamic analyses of peripheral blood from relapsed B-NHL pat
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DALLAS , July 29, 2014 ... Market Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), ... Storage - Global Forecasts & Trends to 2018", published ... and restraints in geographies such as North ... Asia , and the Rest of the ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, applauds the Editorial Board of ... position in opposition to current federal law on ... The New York Times also announces a series ... the issue called "High Time:  An Editorial Series ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... , PHILADELPHIA, July 13 ERT (Nasdaq: ... technology, and other services to the biopharmaceutical, medical device, and related ... 2009 second quarter on Thursday, July 30, 2009 after the market ... at 5:00 PM EDT that day. , , ...
... , SAN JOSE, Calif., July ... of measurement and control solutions for biologics applications today announced ... BIIB ) aimed at evaluating emerging technologies for single-use bioprocessing. ... control algorithms. , , ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 ... first human cancer biochip for HybSelect, febit,s highly automated technology for ... biochip features 115 important genes which are reported to be associated ... , , "Molecular signatures defined ...
Cached Biology Technology:ERT to Announce 2009 Second Quarter Results on July 30, 2009 2Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... -- Fifteen years ago, MIT professor John Essigmann and colleagues ... an HIV drug. They thought if they could induce the ... and eventually die out a strategy that our immune ... such a drug, which caused HIV to mutate at an ... virus from patients in a small clinical trial reported in ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... Institute Associate Professor Marisa Roberto has been awarded the ... the Ordine al Merito della Repubblica Italiana (Order of ... addictive behavior. Traditionally bestowed by the president ... "merit acquired by the nation" in literature, the arts, ...
... been told you,re going on a trip. The only problem ... traveling, or what you,ll do when you get there. ... is on right now. As land use, human population, consumption ... with complex and unpredictable interactions, it,s anybody,s guess where we,ll ...
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
Cached Biology News:U of M researchers find smart decisions for changing environmental times 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: